Extensive phase III clinical studies (Tan et al., 2016; Rosell et al., 2012; Sequist et al., 2013; Wu et al., 2015) have validated EGFR tyrosine kinase inhibitors (EGFR-TKIs) as the preferred first-line treatment for EGFR mutant NSCLC, outperforming chemotherapy in terms of progression-free survival (PFS), objective response rate (ORR), and quality of life (QOL). This evidence concerns the gene EGFR and non-small cell lung carcinoma.